Q & A: Wichita's role in bringing emerging cancer treatment to the region
Dr. Shaker Dakhil and the Cancer Center of Kansas has played a pivotal role in bringing new cancer therapies to Kansas. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 24, 2022 Category: American Health Authors: Shelby Kellerman Source Type: news
Single-cell analysis reveals clues about promising cancer therapy
A team of researchers has uncovered some critical clues about why a significant number of patients relapse from CAR T therapy for blood cancer. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 22, 2022 Category: Universities & Medical Training Source Type: news
Fastest-growing public companies: Revenue spikes for Waltham cancer drug firm
Syndax Pharmaceuticals has toiled for years toward finding cancer therapies that can improve the lives of patients. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 17, 2022 Category: Pharmaceuticals Authors: Grant Welker Source Type: news
SNMMI Image of the Year predicts poor outcomes after heart attack
PET imaging that reveals poor outcomes in patients after a heart attack ha...Read more on AuntMinnie.comRelated Reading:
Dual-tracer PET/CT shows promise in cancer imaging
PET imaging lays foundation for new cancer therapies
PET tracer shows promise for diagnosing breast cancer
Animal study suggests Ga-68 PET FAPI can detect lung fibrosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 15, 2022 Category: Radiology Source Type: news
For Exelixis, collaboration is essential for improving outcomes for patients with cancer
A continuing challenge in cancer therapy is effectively killing cancer cells while protecting healthy tissue. Overcoming this obstacle requires the ability to identify and target cancer-related pathways without disturbing normal cell function. Exelixis was founded in 1994 with an initial focus on turning deep biologic insights into novel cancer therapies that have the potential to improve patient outcomes.
This focus has allowed us to establish a successful commercial franchise around our lead… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 15, 2022 Category: Pharmaceuticals Authors: Michael M. Morrissey, Ph.D. Source Type: news
How Atrium Health researchers are making clinical trials more accessible to underserved populations
With funding from the National Cancer Institute (NCI), researchers at Atrium Health Wake Forest Baptist Medical Center ’s Comprehensive Cancer Center are making it easier for racial and ethnic minorities and underserved patients in North Carolina, Virginia and West Virginia to access the latest cancer treatments through clinical trials.
The NCI CATCH-UP (Create Access to Targeted Cancer Therapy for Underserved Po pulations) grant is congressionally mandated funding to help address disparities in… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 14, 2022 Category: Health Management Authors: Atrium Health Wake Forest Baptist Source Type: news
Key takeaways from ASCO's annual meeting
Last weekend, health care professionals, patients, scientists and biopharmaceutical researchers gathered for the American Society of Clinical Oncology's (ASCO) annual meeting. With over 200 sessions and 2,500 poster presentations on the latest advances in cancer therapy, the future of cancer diagnosis and treatment is promising. (Source: The Catalyst)
Source: The Catalyst - June 10, 2022 Category: Pharmaceuticals Authors: Mike Ybarra Tags: Research and Development Cancer Source Type: news
U.S. FDA approves Foundation Medicine ’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)
FoundationOneCDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solidtumours for whom treatment withRozlytrek may be appropriateThis approval marks the first and only companion diagnostic indication forRozlytrek, and another important milestone intumour-agnostic approaches for people living with rare cancersRoche is a leader in drivingpersonalised healthcare around the world through validated diagnostic tools, genomic insights and a continued focus on drug developmentBasel, 9 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news
Clarity secures IND from FDA for radiotracer for prostate cancer
Clarity Pharmaceuticals has secured investigational new drug approval (IND...Read more on AuntMinnie.comRelated Reading:
Clarity treats first patient in COBRA trial
Clarity launching trial for prostate cancer therapy
Clarity hits milestone in study of radiopharmaceutical
NorthStar partners with Clarity, Monopar
FDA grants rare disease designation to Clarity agent (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 6, 2022 Category: Radiology Source Type: news
Judson appointed Charles W. Ohse Professor of Surgery (Otolaryngology)
Benjamin Judson ’s research interests include investigating outcomes and quality in head and neck cancer therapy. His appointment begins immediately. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 6, 2022 Category: Universities & Medical Training Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
BEERSE, BELGIUM, 26 May 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license a...
Source: Johnson and Johnson - May 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
FAPI-PET shows promise detecting biliary tract cancer
Fibroblast-activation protein inhibitor (FAPI)-PET imaging proved to be superio...Read more on AuntMinnie.comRelated Reading:
Dual-tracer PET/CT shows promise in cancer imaging
FAPI-PET may improve diagnosis of gastric cancer
Ga-68 radiotracer outperforms F-18 FDG in lung cancer staging
New tracer bests FDG for diagnosing liver cancer
PET imaging lays foundation for new cancer therapies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 23, 2022 Category: Radiology Source Type: news
Study identifies new molecular target for cancer therapy
Researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) have identified a new molecular drug target that could result in new cancer drugs with fewer side effects.
Previous studies have shown that vascular endothelial growth factor-A (VEGF-A) - a potent cytokine (signaling protein) - and dopamine (a neurotransmitter/neurohormone) play essential roles in many physiological and pathological functions. (Source: World Pharma News)
Source: World Pharma News - May 20, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Car T-cell therapy shows early promise in treating gastric cancers
Chinese researchers say interim trial results suggest approach could be important for those with advanced tumoursAn experimental cancer therapy that infuses designer immune cells into patients has shown early promise in a clinical trial by shrinking tumours in the digestive system.Interim results from the first phase of the clinical trial found that the tumours in nearly half – 48.6% – of the 37 patients treated so far reduced in size after the therapy.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - May 9, 2022 Category: Science Authors: Ian Sample Science editor Tags: Cancer research Science Health China UK news Medical research World news Source Type: news
